EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial

Mingkun Zhang, Yuan Qin, Junhao Wan, Zelin Tian, Ziyu Zhang, Xulong Zhu, Dong Fan, Liu Yang, Lan Hou, Huan Zhang, Ge Zhao, Ting Wang und 1 weitere

Breast Cancer Research and Treatment · 2026-11 · 220 (1)

DOI: 10.1007/s10549-026-08091-4 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 09.11.2026. Verfasst von Mingkun Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, 710032, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleEpirubicinCyclophosphamidePaclitaxelDocetaxelAlbuminsNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesMiddle AgedAdultReceptors, EstrogenReceptors, ProgesteroneDrug Administration ScheduleTaxoidsTreatment OutcomeAgedPathologic Complete ResponseNeoplasm Staging

Stichwörter der Autor:innen

Dose-dense nab-paclitaxelHR+/HER2- breast cancerNeoadjuvant chemotherapyResidual Cancer Burden 0/Ⅰ (RCB 0/Ⅰ)

Substanzen

EpirubicinCyclophosphamidePaclitaxelDocetaxel130-nm albumin-bound paclitaxelAlbuminsErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneTaxoids

Autor:innen und Institutionen

  • Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, 710032, China.
  • Department of Surgical Oncology, Shaanxi Provincial People's hospital, Xi'an, Shanxi, 710068, China.
  • Department of General Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, 710038, China.
  • Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, 710032, China. ting_w100@126.com.
  • Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, 710032, China. vascularzhang@163.com.

Zitieren

APA

Zhang, M., Qin, Y., Wan, J., Tian, Z., Zhang, Z., Zhu, X., Fan, D., Yang, L., Hou, L., Zhang, H., Zhao, G., Wang, T., & Zhang, J. (2026). Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial. Breast Cancer Research and Treatment, 220(1). https://doi.org/10.1007/s10549-026-08091-4

Vancouver

Zhang M, Qin Y, Wan J, Tian Z, Zhang Z, Zhu X, et al. Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial. Breast Cancer Research and Treatment. 2026;220(1). doi:10.1007/s10549-026-08091-4

BibTeX
@article{Zhang2026,
  author = {Zhang, Mingkun and Qin, Yuan and Wan, Junhao and Tian, Zelin and Zhang, Ziyu and Zhu, Xulong and Fan, Dong and Yang, Liu and Hou, Lan and Zhang, Huan and Zhao, Ge and Wang, Ting and Zhang, Juliang},
  title = {Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  volume = {220},
  number = {1},
  doi = {10.1007/s10549-026-08091-4}
}
Kostenlos starten →